DING, JINXI

Release date:2016-05-17  Release:

DING, JINXI

Professor of Social and Administrative Pharmacy

Vice Dean of School of International Pharmaceutical Business of China Pharmaceutical University.

Phone: 86-25-86185198

Email:13605152326@163.com

Research Summary

Professor Ding’s researches focus on pharmaceutical intellectual property and regulatory science. In recent years, he extends his fields to health insurance payment and centralized drug procurement system.

As a graduate supervisor, Professor Ding enrolls and helps graduates majoring in social and administrative pharmacy (pharmaceutical policies and regulations as well as pharmaceutical intellectual property direction).

Professor Ding takes the key researches and projects of State Council, National Social and Science Foundation as well as the State Intellectual Property Office. He has published more than 78 pieces of papers with one in SCI and 27 in CSSCI.

Education

2011 Ph.D., Agricultural Economy and Management, Nanjing Agricultural University

1999M.S., International Economic Law, Nanjing University

1994B.S., Chinese Pharmacy, China Pharmaceutical University

Academic Experience

2007-PresentThe State Council Intellectual Property Strategy OfficeThink tank member

2009-Present Intellectual Property Committee of China Pharmaceutical Association Member

2010- Present  Intellectual Property Committee of Jiangsu Lawyer AssociationMember

2015- Present  Expert Tank of National Drug PolicyMember

2015- Present  Intellectual Property Committee of China Health Law Society Vice-Chairman

Awards and Honors

2013 Establishment and Development of Training System for Interdisciplinary Talents of Chinese Pharmacy Administration

First Price of Teaching AchievementJiangsu Provincial Education Department

2012 Young and mid-age Academic leader in Qinglan Program of Jiangsu ProvinceJiangsu Provincial Education Department

2011 Innovation and Practice of Pharmaceutical Law Curriculum Group

Second Price of Teaching Achievement

Jiangsu Provincial Education Department

2009Pioneer of New Long MarchPeople's Government of Jiangsu Province

2008 Contribution award of National intellectual property strategy FormulationState Council

2015 Study ofClassification Management of Drug Price with Health Insurance Payment – Empirical Analysis based on Brilique and Norvasc

Outstanding Paper AwardChina Pharmaceutical Association

2014 Analysis of price difference and policy formation of brand-name and generic drugs in China

Outstanding Paper Award China Pharmaceutical Association

2014 Several issues about Chinese legal definition of new chemical entity under the framework of data protection regime

Outstanding Paper AwardChina Pharmaceutical Association

2014 Pharmaceutical Corporate Patent Strategy under the Framework of the Strategic Emerging Industries

Outstanding Paper AwardChina Pharmaceutical Association

2012 Drug Electronic Supervision Policy under the Twelfth Five-Year Guideline for Drug Safety  

Outstanding Paper AwardChina Pharmaceutical Association

2011 The Unify Operation Pattern of Drug Reimbursement List under thePolicy of New Medical Reform

Outstanding Paper AwardChina Pharmaceutical Association

Publications

Books

[1]Ding J XPolicy interpretation and strategic management of innovative drug R&D[M]2011Jiangsu Science and Technology Press

[2] Fang Y,Ding J Xpharmaceutical administration and regulation [M]2012Xian Jiaotong University Press

[3] Shao RDing J X, et al, Theory and Practice of Chinese Pharmaceutical Law[M]2011China medical science press


Papers and Articles

[1]Ding J X,Sun X D, Research on Impact of Innovation Policy under Framework of Institutional Strategic Theory----Based on empirical study on biomedical high-tech enterprises in Jiangsu Province[J], Soft Science,2015,25(11), 61-68

[2]Ding J X,Xiao H Q,Li w,Yan J Z,Liu Y Y, Evaluation of Generic Substitution Regime in US Public Health Care - Empirical Analysis based on Medicaid programs [J], Northwest Population Journal,2015,36(05), 101-106

[3]Ding J X,Hu X Y,Ji N,Study of the Indicator system of the generic drugs market access value in China, Chinese Journal of Pharmaceuticals,2015,46(1), 107-112

[4]Ding J X,Ren H Y,Yao X F,Xu Z H, Several issues about Chinese Legal Definition of New Chemical Entity under the Framework of Data Protection Regime, Chinese Journal of New Drugs,2015,24(6), 610-615

[5]Ding J X,Fu L Y,Meng L L,Bai G L,Comparative Study on Post-Market Risk Management of Sibutramine in China and America and its Enlightenment, Chinese Journal of New Drugs,2015,24(14), 1561-1567

[6]Ding J X,Meng L L,Zhang J F,Pharmaceutical Corporate Patent Strategy and Innovation Capacity-Building under the Framework of the Strategic Emerging Industries, Chinese Pharmaceutical Journal,2014,49(5), 431-436

[7]Ding J X,Liu W J,Li W,Liu Y Y,Bai G L,Analysis of orphan drug accessibility and marketing authorization system in China,Journal of China Pharmaceutical University2014,451),111-117

[8]Ding J X,Liu Y Y,Hu X Y,Dou J Y,Ji N,Jing R H,Comparative Analysis on the Marketing Approval System of Generic Drugs between China and America, Chinese Journal of Pharmaceuticals,2014,45(2),190-198

[9]Ding J X,Zhang J F,Fang Y,Wang Z,He M Y,Gu Y,Evaluation and Analysis of Political Causes of Current Status of Patent Pledge in Strategic Emerging Bio-medical Industry, Forum on Science and Technology in China20132),72-77

[10]Ding J X,He M Y,Research on Multiple Component Facility of Intellectual Property of American,Chinese Journal of Pharmaceuticals ,2013, 44(7),734-740

[11]Ding J X,He M Y,Zhang J F,Study on Incentive Policy of Intellectual Property Pledge Financing- Empirical Analysis based on Yusen Model,Modern Business Trade Industry,2013(9)106-108

[12] Ding J X,Na J I, Xiao-Ting L I, et al. Analysis of Biopharmaceutical Innovation Investment in China and Its Policy Causes——On the Basis of the Status Quo of Innovation Investment in United States,Europe and China by Empirical evaluation[J]. Scientific Management Research, 2012.

[13] Ding J X, Wang Y W, Xiao-Xue H E, et al. Definition of new chemical entity in pharmaceutical data protection regime—an empirical analysis of Actavis vs.FDA on Vyvanse[J]. Chinese Journal of New Drugs & Clinical Remedies, 2012, 31(11):652-657.

[14] Ding J X, Hui L U, Zhuo-Huan X U, et al. Study on Drug Electronic Supervision System of California in USA[J]. China Pharmacy, 2012.

[15] Ding J X, Xiao-Ting L I, Na J I, et al. Quantitative evaluation of the performance of incentive policy institution in biomedical innovation[J]. Shanghai Medical & Pharmaceutical Journal, 2012.

[16Ding J X,Wang Y W,Qin L,Empirical Analysis of Innovative Drug Re-evaluation Mechanism——Based on Case of “Etanercept” [J]. Chinese Journal of Drug Evaluation,2012,29(2),183-187

[17]Ding J X,Li X T,Gu H, Influence of New Rural Cooperative Medical System on Farmers’ Medical Burden ----Based on Research Data of Jiangsu[J].Anhui and Shanxi Issues in Agricultural Economy,2012(11)

[18]Ding J X,Li Y,Wang Y W, Comparing Analysis of the Innovative Drug Monitoring Period System between China and Japan[J]. Chinese Journal of New Drugs,2012,21(16), 1840-1845

[19]Ding J X,Deng M,Bai G L, Pharmaceutical Data Protection Regime for Pediatric Drug in America and Analysis of Its Impact on Children’s Drug Use[J]. Chinese Pharmaceutical Journal,2012,47(10),749-752

[20] Liang H G, Ding J X, Xue Y J, China Drugs Innovation and Policy Environment[J]. Drug Discovery Today,2011,16(1),01-03

[21] Ding J X, Luo X W, Wang Y W. Evaluation of Japanese data protection system from the perspective of economics——the empirical analysis based on the performance of reexamination Policy on Japanese innovative drugs[J]. Shanghai Medical & Pharmaceutical Journal, 2011.

[22] Ding J X, Yi-Lin M A. Comparison and analysis of the venture capital mechanisms of innovative drugs in China and America [J]. Chinese Journal of New Drugs, 2011, 20(23):2300-2307.

[23] Ding J X, Yuan L I, Gao Q. Research on Drug Electronic Supervision Policy under the Framework of National Essential Drug System[J]. China Pharmacy, 2011, 22(48):4513-4516.

[24] Ding J X, Meng L L, Luo X W. Research on Incentive Policies of Innovative Drugs in Japan and its Enlightenment to China—an Empirical Study on Research and Development of edaravone[J]. Chinese Journal of New Drugs & Clinical Remedies, 2011, 30(11):839-847.

[25] Ding J X. Study on the Accepted Conditions forthe Non-infringement Action of Pharmaceutical Patent——Querying the article 18 of[2009]21 judicial interpretation[J]. Hebei Law Science, 2011.

[26] Ding J X. Comparing the Intellectual Property Financing Policies between China and Japan:A Case Study of Innovative Drugs' Patent-Pledging[J]. Contemporary Economy of Japan, 2011.

[27]Ding J X,Gu H,Geng L,Zhao Y,Analysis for Payment Method of Medical Care Expenses Under the Framework of New Health Care System Reform[J],Social Sciences in Yunnan,2011(01),110-115

[28]Ding J X,Shao M L,Gu H, Comparison of Public Health Insurance Regime between China and the U.S [J], Northwest Population Journal,2011,326),01-08

[29]Ding J X,Guo X,Geng L, U.S. Dedication Doctrine and its Inspiration for China ——Empirical Analysis of "Pfizer" v.s. " Ranbaxy and Teva" Biomedical Patent Infringement Lawsuit[J]  Intellectual Property,2011(10),92-96

[30]Ding J X,Sun X D,Ji N,Shao W J, Research on Sino- U.S. legal protection regime of Orphan drug accessibility [J], Chinese Pharmaceutical Journal,2011(14), 1129-1131

[31]Yao X F, Ding J X, Shao R, et al. A Comparison of Innovative Drug Research and Development Abilities between China and Foreign Countries based on An Evaluation System of Pharmaceutical Technology Innovation[J]. Chinese Journal of New Drugs, 2010.

[32]Ding J X,Luo X W, Research on the Pricing System of Innovative Drug in Japan Price[J], Theory and Practice,2010

[33]Ding J X,Yang J G, Study on European Admittance System of Registration of Traditional Chinese Medicine[J] ,International Business,2010

[34] Ding J X, Min Z. The Comparative Study on Supervision and Incentive Policies of Sino-US during the Innovative Drug R&D[J]. Chinese Journal of New Drugs, 2009, 18(5):387-392.

[35] Ding J X, Liu X. Comparative Analysis for the Institutions of the Adulterated and Misbranded Drug in China and USA[J]. Chinese Journal of New Drugs, 2009.

[36]Ding J X,Yao X F, Complete Bar or Flexible Bar? ---Discussion on the Application of Estoppels from a Patent Case[J], Electronics Intellectual Property,2009

[37] Ding J X, Han B B. Comparative Analysis of Pharmaceutical Patent Linkage System in China and USA[J]. Chinese Journal of Pharmaceuticals, 2008, 39(12):950-955.

[38]Ding J X, A Brief Study on Intellectual Property in Setting New Drug Research under the Framework of TRIPS[J], Chinese Journal of Pharmaceuticals,2006